North America Cryogenic Label Printer Sales to register US 140.0 million by 2033 Amid Expanding Laborato - Benzinga
| GBLX Stock | USD 0 0 76.00% |
Slightly above 53% of GB Sciences' investor base is interested to short. The analysis of overall sentiment of trading GB Sciences pink sheet suggests that many investors are impartial at this time. GB Sciences' investing sentiment can be driven by a variety of factors including economic data, GB Sciences' earnings reports, geopolitical events, and overall market trends.
GBLX |
North America Cryogenic Label Printer Sales to register US 140.0 million by 2033 Amid Expanding Laborato Benzinga
Read at news.google.com
 |
GB Sciences Fundamental Analysis
We analyze GB Sciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GB Sciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GB Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Asset
Current Asset Comparative Analysis
GB Sciences is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
GB Sciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with GB Sciences pink sheet to make a market-neutral strategy. Peer analysis of GB Sciences could also be used in its relative valuation, which is a method of valuing GB Sciences by comparing valuation metrics with similar companies.
Peers
GB Sciences Related Equities
| SPRC | Scisparc | 4.76 | ||||
| CVALF | Covalon Technologies | 1.15 | ||||
| ATBPF | Antibe Therapeutics | 0.00 | ||||
| CMVLF | Cellectis | 0.00 |
Additional Tools for GBLX Pink Sheet Analysis
When running GB Sciences' price analysis, check to measure GB Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GB Sciences is operating at the current time. Most of GB Sciences' value examination focuses on studying past and present price action to predict the probability of GB Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GB Sciences' price. Additionally, you may evaluate how the addition of GB Sciences to your portfolios can decrease your overall portfolio volatility.